title: Your business in court and at Federal agencies: 2011-2012.
abstract: FDA transparency effort continued, including the Secretary's adopting eight measures to improve access to Agency information and activities. A continuing problem was shortages of prescription drugs, which probably was enhanced by increased manufacturing recalls. FDA issued more device Guidances for regulatory clarity. Enforcement involving drugs and devices increased, including GMP and GLP enforcement and surveillance of internet claims. The Supreme Court decided generic drug manufacturers may cause the FDA to revise incorrectly listed use codes, and pharmaceutical detailers may not receive overtime payments. FDA initiated implementation of the Food Safety and Modernization Act, including two pilot tracking systems for supply chain tracing and to determine how quickly data can be gathered. The Agency issued guidance for new dietary supplements. FDA failed to impose graphic labeling requirements on the tobacco industry, but established it can regulate electronic cigarettes as tobacco. The Agency issued guidelines for the use of nanomaterials in cosmetics, and reviewed the effectiveness of sunscreen products. FDA is being given more authority over larger areas of the U.S. economy, but its resources are not increased proportionately. The pharmaceutical industry made major payments for alleged violations of the Drug Rebate Statute, Anti-Kickback Statute, Wholesale Price and Off-Label Use prohibitions. The government continues using the Responsible Corporate Officer doctrine to make company managers responsible for corporate conduct about which they had no knowledge. Companies should have a robust compliance program in effect. The FTC and the SEC continue their oversight activities, including SEC's enforcement of the Foreign Corrupt Practices Act. The defense of product liability litigation continues grappling with federal preemption of state laws.
authors.forename: John B
authors.initials: JB
authors.lastname: Reiss
authors.forename: Dawn
authors.initials: D
authors.lastname: Crowder
authors.forename: Brittany
authors.initials: B
authors.lastname: McCabe
authors.forename: Marisa
authors.initials: M
authors.lastname: DeFeo
authors.forename: Marta
authors.initials: M
authors.lastname: Rifin
authors.forename: Meghan
authors.initials: M
authors.lastname: Talbot
mesh_terms: D004348:Drug Labeling / Q000331:legislation & jurisprudence; D005515:Food Labeling / Q000331:legislation & jurisprudence; D006077:Government Agencies; D006801:Humans; D007880:Legislation, Drug; D007881:Legislation, Food; D062307:Medical Device Legislation; D019460:Tobacco Industry / Q000331:legislation & jurisprudence; D062789:Tobacco Products; D014481:United States